TY - JOUR
T1 - Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings
AU - Velthorst, Eva
AU - Mollon, Josephine
AU - Murray, Robin M.
AU - de Haan, Lieuwe
AU - Germeys, Inez Myin
AU - Glahn, David C.
AU - van der Ven, Els
AU - Arango, Celso
AU - Bernardo, Miguel
AU - Guloksuz, Sinan
AU - Delespaul, Philippe
AU - Mezquida, Gisela
AU - Amoretti, Silvia
AU - Bobes, Julio
AU - Saiz, Pilar A.
AU - García-Portilla, María Paz
AU - Sanjuan, Julio
AU - Aguilar, Eduardo J.
AU - Santos, José Luis
AU - Jiménez-López, Estela
AU - Arrojo, Manuel
AU - Carracedo, Angel
AU - López, Gonzalo
AU - González-Peñas, Javier
AU - Parellada, Mara
AU - Atbaşoğlu, Cem
AU - Saka, Meram Can
AU - Üçok, Alp
AU - Alptekin, Köksal
AU - Akdede, Berna
AU - Binbay, Tolga
AU - Altınyazar, Vesile
AU - Ulaş, Halis
AU - Yalınçetin, Berna
AU - Gümüş-Akay, Güvem
AU - Beyaz, Burçin Cihan
AU - Soygür, Haldun
AU - Cankurtaran, Eylem Şahin
AU - Kaymak, Semra Ulusoy
AU - Maric, Nadja P.
AU - Mihaljevic, Marina M.
AU - Petrovic, Sanja Andric
AU - Mirjanic, Tijana
AU - Del-Ben, Cristina Marta
AU - Di Forti, Marta
AU - Gayer-Anderson, Charlotte
AU - Jones, Peter B.
AU - Jongsma, Hannah E.
AU - Kirkbride, James B.
AU - La Cascia, Caterina
AU - Lasalvia, Antonio
AU - Tosato, Sarah
AU - Llorca, Pierre Michel
AU - Menezes, Paulo Rossi
AU - Morgan, Craig
AU - Quattrone, Diego
AU - Santos, José Luis
AU - Sanjuán, Julio
AU - Selten, Jean Paul
AU - Szoke, Anita
AU - Tarricone, Ilaria
AU - Tortelli, Andrea
AU - McGuire, Philip
AU - Valmaggia, Lucia R.
AU - Kempton, Matthew J.
AU - van der Gaag, Mark
AU - Riecher-Rössler, Anita
AU - Bressan, Rodrigo
AU - Barrantes-Vidal, Neus
AU - Nelson, Barnaby
AU - McGorry, Patrick D.
AU - Pantelis, Christos
AU - Krebs, Marie Odile
AU - Ruhrmann, Stephan
AU - Sachs, Gabriele
AU - Rutten, Bart P.F.
AU - Os, Jim van
AU - Monsonet Bardaji, Manel
N1 - © 2021. The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/1/7
Y1 - 2021/1/7
N2 - Important questions remain about the profile of cognitive impairment in psychotic disorders across adulthood and illness stages. The age-associated profile of familial impairments also remains unclear, as well as the effect of factors, such as symptoms, functioning, and medication. Using cross-sectional data from the EU-GEI and GROUP studies, comprising 8455 participants aged 18 to 65, we examined cognitive functioning across adulthood in patients with psychotic disorders (n = 2883), and their unaffected siblings (n = 2271), compared to controls (n = 3301). An abbreviated WAIS-III measured verbal knowledge, working memory, visuospatial processing, processing speed, and IQ. Patients showed medium to large deficits across all functions (ES range = –0.45 to –0.73, p < 0.001), while siblings showed small deficits on IQ, verbal knowledge, and working memory (ES = –0.14 to –0.33, p < 0.001). Magnitude of impairment was not associated with participant age, such that the size of impairment in older and younger patients did not significantly differ. However, first-episode patients performed worse than prodromal patients (ES range = –0.88 to –0.60, p < 0.001). Adjusting for cannabis use, symptom severity, and global functioning attenuated impairments in siblings, while deficits in patients remained statistically significant, albeit reduced by half (ES range = –0.13 to –0.38, p < 0.01). Antipsychotic medication also accounted for around half of the impairment in patients (ES range = –0.21 to –0.43, p < 0.01). Deficits in verbal knowledge, and working memory may specifically index familial, i.e., shared genetic and/or shared environmental, liability for psychotic disorders. Nevertheless, potentially modifiable illness-related factors account for a significant portion of the cognitive impairment in psychotic disorders.
AB - Important questions remain about the profile of cognitive impairment in psychotic disorders across adulthood and illness stages. The age-associated profile of familial impairments also remains unclear, as well as the effect of factors, such as symptoms, functioning, and medication. Using cross-sectional data from the EU-GEI and GROUP studies, comprising 8455 participants aged 18 to 65, we examined cognitive functioning across adulthood in patients with psychotic disorders (n = 2883), and their unaffected siblings (n = 2271), compared to controls (n = 3301). An abbreviated WAIS-III measured verbal knowledge, working memory, visuospatial processing, processing speed, and IQ. Patients showed medium to large deficits across all functions (ES range = –0.45 to –0.73, p < 0.001), while siblings showed small deficits on IQ, verbal knowledge, and working memory (ES = –0.14 to –0.33, p < 0.001). Magnitude of impairment was not associated with participant age, such that the size of impairment in older and younger patients did not significantly differ. However, first-episode patients performed worse than prodromal patients (ES range = –0.88 to –0.60, p < 0.001). Adjusting for cannabis use, symptom severity, and global functioning attenuated impairments in siblings, while deficits in patients remained statistically significant, albeit reduced by half (ES range = –0.13 to –0.38, p < 0.01). Antipsychotic medication also accounted for around half of the impairment in patients (ES range = –0.21 to –0.43, p < 0.01). Deficits in verbal knowledge, and working memory may specifically index familial, i.e., shared genetic and/or shared environmental, liability for psychotic disorders. Nevertheless, potentially modifiable illness-related factors account for a significant portion of the cognitive impairment in psychotic disorders.
KW - SCHIZOPHRENIA-PATIENTS
KW - GENETIC RISK
KW - RELIABILITY
KW - VALIDITY
KW - DEFICITS
KW - IMPAIRMENT
KW - CHILDHOOD
KW - EPISODE
KW - DECLINE
KW - ABILITY
UR - http://www.scopus.com/inward/record.url?scp=85099043499&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/29af395e-4acd-3cc8-b642-8f16d407b6f0/
U2 - 10.1038/s41380-020-00969-z
DO - 10.1038/s41380-020-00969-z
M3 - Artículo
C2 - 33414498
AN - SCOPUS:85099043499
SN - 1359-4184
VL - 26
SP - 4529
EP - 4543
JO - Molecular Psychiatry
JF - Molecular Psychiatry
IS - 8
ER -